These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 17950105

  • 21. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW, Ose L, Marais AD.
    J Pediatr; 2003 Jul 15; 143(1):74-80. PubMed ID: 12915827
    [Abstract] [Full Text] [Related]

  • 23. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
    Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, Quagliarini F, Antonini R, Romeo S, Baroni MG.
    Nutr Metab Cardiovasc Dis; 2009 Nov 15; 19(9):660-6. PubMed ID: 19632099
    [Abstract] [Full Text] [Related]

  • 24. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV, Yegorova YV.
    Kardiol Pol; 2006 Jan 15; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [Abstract] [Full Text] [Related]

  • 25. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M.
    Metabolism; 2005 Aug 15; 54(8):1065-74. PubMed ID: 16092057
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B, Jeamanukulkit N, Piamsomboon C, Chawantanpipat C, Khanacharoen I.
    J Med Assoc Thai; 2004 Nov 15; 87(11):1281-5. PubMed ID: 15825700
    [Abstract] [Full Text] [Related]

  • 27. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb 15; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 29. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May 15; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 30. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1188-94. PubMed ID: 15063428
    [Abstract] [Full Text] [Related]

  • 31. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, MIRACL Study Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2186-96. PubMed ID: 19497447
    [Abstract] [Full Text] [Related]

  • 32. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 09; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 33. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am J Cardiol; 2009 Feb 15; 103(4):515-22. PubMed ID: 19195513
    [Abstract] [Full Text] [Related]

  • 35. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P.
    Curr Med Res Opin; 2004 Aug 15; 20(8):1321-7. PubMed ID: 15324535
    [Abstract] [Full Text] [Related]

  • 36. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 15; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 37. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, Abramowicz D.
    Transplantation; 2006 Sep 27; 82(6):771-8. PubMed ID: 17006324
    [Abstract] [Full Text] [Related]

  • 38. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC, Chu CH, Wei MC, Keng HM, Lu CC, Sun CC, Lee JK, Chuang MJ, Wang MC, Tai MH.
    Exp Biol Med (Maywood); 2006 Jun 27; 231(6):1010-5. PubMed ID: 16741040
    [Abstract] [Full Text] [Related]

  • 39. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
    Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS.
    Am Heart J; 2004 Oct 27; 148(4):635-40. PubMed ID: 15459594
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC, Sanchez-Ballester E, Albalat-Galera R, Berzosa-Sanchez M, Herrera-Ballester A.
    J Cardiovasc Pharmacol Ther; 2008 Sep 27; 13(3):183-8. PubMed ID: 18635754
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.